BioCentury | Sep 27, 2018
Distillery Therapeutics

Cancer

...in Phase III testing for B cell lymphoma. Hercules Pharmaceuticals B.V. and Boston University have CB7993113...
BioCentury | Feb 29, 2016
Emerging Company Profile

Hercules' IDO alternative

...reactions, including hepatotoxicity. Hercules has not yet published preclinical data for its lead AHR inhibitor, CB7993113...
...from a mouse xenograft model of oral cancer showed that 90% of animals treated with CB7993113...
...in a series A round to fund development through Phase IIa testing. The company expects CB7993113...
Items per page:
1 - 2 of 2